BackClaritev Overview
Claritev Corporation

Claritev Target Price

See Claritev's analyst price targets ($51) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$37.64

Average Target Price

$50.8035% upside

5 analysts in the last 4 months

High: $73 | Low: $37

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-20BarclaysGlen Santangelo$406.3% upsideOpen
2026-08-12Piper SandlerJessica Tassan$7393.9% upsideOpen
2026-08-10Canaccord Genuity$4314.2% upsideOpen
2026-07-21Canaccord Genuity$371.7% downsideOpen
2026-06-03Piper Sandler$6162.1% upsideOpen
2026-04-24Barclays$2825.6% downsideOpen
2026-02-24Wells FargoStan Berenshteyn$3020.3% downsideOpen
2026-02-24Guggenheim$381% upsideOpen
2026-01-08Wells FargoStan Berenshteyn$3312.3% downsideOpen

Claritev (CTEV) FAQ

Claritev posts a target price of $51. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $51 for CTEV means covering analysts, on average, see the stock 35.0% upside of $37.64 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for CTEV's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Claritev's other metric pages and overview cover the third.

Judging Claritev against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $51 here, then scan peer and history charts to see if the gap is persistent.